Advertisement
Advertisement
BMRN
BioMarin Pharmaceuticals Inc
57.29
USDSponsored
+4.55
+8.63%
May 29, 15:59 UTC -4
Closed
After-Market
57.16
-0.13
-0.22%
BMRN Earnings Reports
Positive Surprise Ratio
BMRN beat 29 of 42 last estimates.
69%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$946.14M
/$0.76
Implied change from Q1 26 (Revenue/ EPS)
+23.48%
/+40.74%
Implied change from Q2 25 (Revenue/ EPS)
+14.63%
/-38.21%
BioMarin Pharmaceuticals Inc earnings per share and revenue
On May 04, 2026, BMRN reported earnings of 0.54 USD per share (EPS) for Q1 26, missing the estimate of 0.76 USD, resulting in a -29.47% surprise. Revenue reached 766.21 million, compared to an expected 771.12 million, with a -0.64% difference. The market reacted with a -4.00% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 17 analysts forecast an EPS of 0.76 USD, with revenue projected to reach 946.14 million USD, implying an increase of 40.74% EPS, and increase of 23.48% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Roivant Sciences Ltd. Common Shares
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.35
Actual
-$0.57
Surprise
-64.63%
Belite Bio, Inc - ADR
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.68
Surprise
-4.87%
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.04
Surprise
+12.85%
Gossamer Bio, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.20
Surprise
-18.62%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
OS Therapies Incorporated
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.27
Surprise
-49.83%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
FAQ
What were BioMarin Pharmaceuticals Inc's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, BioMarin Pharmaceuticals Inc reported EPS of $0.54, missing estimates by -29.47%, and revenue of $766.21M, -0.64% below expectations.
How did the market react to BioMarin Pharmaceuticals Inc's Q1 2026 earnings?
The stock price moved down -4%, changed from $55.46 before the earnings release to $53.24 the day after.
When is BioMarin Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for BioMarin Pharmaceuticals Inc's next earnings report?
Based on 17
analysts, BioMarin Pharmaceuticals Inc is expected to report EPS of $0.76 and revenue of $946.14M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement